These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 14638772)

  • 21. Clostridium difficile toxin A carboxyl-terminus peptide lacking ADP-ribosyltransferase activity acts as a mucosal adjuvant.
    Castagliuolo I; Sardina M; Brun P; DeRos C; Mastrotto C; Lovato L; Palù G
    Infect Immun; 2004 May; 72(5):2827-36. PubMed ID: 15102793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant effect of non-toxic mutants of E. coli heat-labile enterotoxin following intranasal, oral and intravaginal immunization.
    De Magistris MT; Pizza M; Douce G; Ghiara P; Dougan G; Rappuoli R
    Dev Biol Stand; 1998; 92():123-6. PubMed ID: 9554265
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The level of protection against rotavirus shedding in mice following immunization with a chimeric VP6 protein is dependent on the route and the coadministered adjuvant.
    Choi AH; McNeal MM; Flint JA; Basu M; Lycke NY; Clements JD; Bean JA; Davis HL; McCluskie MJ; VanCott JL; Ward RL
    Vaccine; 2002 Mar; 20(13-14):1733-40. PubMed ID: 11906760
    [TBL] [Abstract][Full Text] [Related]  

  • 24. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.
    Pizza M; Giuliani MM; Fontana MR; Douce G; Dougan G; Rappuoli R
    Int J Med Microbiol; 2000 Oct; 290(4-5):455-61. PubMed ID: 11111926
    [No Abstract]   [Full Text] [Related]  

  • 25. Immunomodulation using bacterial enterotoxins.
    Simmons CP; Ghaem-Magami M; Petrovska L; Lopes L; Chain BM; Williams NA; Dougan G
    Scand J Immunol; 2001 Mar; 53(3):218-26. PubMed ID: 11251877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mucosal adjuvanticity of two nontoxic mutants of Escherichia coli heat-labile enterotoxin varies with immunization routes.
    Park EJ; Chang JH; Kim JS; Yum JS; Chung SI
    Exp Mol Med; 2000 Jun; 32(2):72-8. PubMed ID: 10926118
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Plasmid vectors encoding cholera toxin or the heat-labile enterotoxin from Escherichia coli are strong adjuvants for DNA vaccines.
    Arrington J; Braun RP; Dong L; Fuller DH; Macklin MD; Umlauf SW; Wagner SJ; Wu MS; Payne LG; Haynes JR
    J Virol; 2002 May; 76(9):4536-46. PubMed ID: 11932419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mutants of type II heat-labile enterotoxin LT-IIa with altered ganglioside-binding activities and diminished toxicity are potent mucosal adjuvants.
    Nawar HF; Arce S; Russell MW; Connell TD
    Infect Immun; 2007 Feb; 75(2):621-33. PubMed ID: 17118982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically detoxified mutants of heat-labile toxin from Escherichia coli are able to act as oral adjuvants.
    Douce G; Giannelli V; Pizza M; Lewis D; Everest P; Rappuoli R; Dougan G
    Infect Immun; 1999 Sep; 67(9):4400-6. PubMed ID: 10456880
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Significance of Enterotoxigenic Escherichia coli (ETEC) Heat-Labile Toxin (LT) Enzymatic Subunit Epitopes in LT Enterotoxicity and Immunogenicity.
    Huang J; Duan Q; Zhang W
    Appl Environ Microbiol; 2018 Aug; 84(15):. PubMed ID: 29802193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of ADP-ribosylation and G(M1)-binding activity in the mucosal immunogenicity and adjuvanticity of the Escherichia coli heat-labile enterotoxin and Vibrio cholerae cholera toxin.
    de Haan L; Verweij W; Agsteribbe E; Wilschut J
    Immunol Cell Biol; 1998 Jun; 76(3):270-9. PubMed ID: 9682971
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin.
    Klipstein FA; Engert RF; Clements JD; Houghten RA
    Infect Immun; 1984 Mar; 43(3):811-6. PubMed ID: 6365784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective mucosal immunity to ocular herpes simplex virus type 1 infection in mice by using Escherichia coli heat-labile enterotoxin B subunit as an adjuvant.
    Richards CM; Aman AT; Hirst TR; Hill TJ; Williams NA
    J Virol; 2001 Feb; 75(4):1664-71. PubMed ID: 11160664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin.
    Takahashi I; Marinaro M; Kiyono H; Jackson RJ; Nakagawa I; Fujihashi K; Hamada S; Clements JD; Bost KL; McGhee JR
    J Infect Dis; 1996 Mar; 173(3):627-35. PubMed ID: 8627026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin (LT).
    Cheng E; Cárdenas-Freytag L; Clements JD
    Vaccine; 1999 Aug; 18(1-2):38-49. PubMed ID: 10501233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 37. GITR contributes to the systemic adjuvanticity of the Escherichia coli heat-labile enterotoxin.
    Tamayo E; Postigo J; González J; Fernández-Rey M; Iglesias M; Santiuste I; Riccardi C; Rappuoli R; Del Giudice G; Merino R; Merino J
    Eur J Immunol; 2010 Mar; 40(3):754-63. PubMed ID: 20017194
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the reactogenicity, adjuvanticity and antigenicity of LT(R192G) and LT(R192G/L211A) by intradermal immunization in mice.
    Maciel M; Smith M; Poole ST; Laird RM; Rollenhagen JE; Kaminski RW; Wenzel H; Bourgeois AL; Savarino SJ
    PLoS One; 2019; 14(11):e0224073. PubMed ID: 31682624
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune modulation by the cholera-like enterotoxins: from adjuvant to therapeutic.
    Williams NA; Hirst TR; Nashar TO
    Immunol Today; 1999 Feb; 20(2):95-101. PubMed ID: 10098329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine.
    Tamura S; Yamanaka A; Shimohara M; Tomita T; Komase K; Tsuda Y; Suzuki Y; Nagamine T; Kawahara K; Danbara H
    Vaccine; 1994 Apr; 12(5):419-26. PubMed ID: 8023550
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.